Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
M.. Pereira Barbosaa, A.. Bugalho de Almeidab, C.. Pereirac,, , C.-W. Chend, P.. Georgioue, G.. Peacheye
a Servi??o de Imunoalergologia, Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
b Cl??nica Universit??ria de Pneumologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
c Novartis Farma – Produtos Farmaceuticos S.A., Avenida Professor Doutor Cavaco Silva, n.?? 10E, Taguspark, 2740-255 Porto Salvo, Portugal
d Novartis Pharmaceuticals Corporation, One Health Plaza East Hanover, NJ 07936-1080, USA
e Novartis Pharmaceuticals UK Limited, Wimblehurst Road Horsham, West Sussex RH12 5AB, UK
Related article:

The real life effectiveness, safety and the use of omalizumab for Portuguese patients with uncontrolled persistent allergic asthma are not sufficiently well known. The objective of this report was to make an evaluation, in a post-marketing, non-interventional, observational registry, of the Portuguese population included in the eXpeRience study.


The methods used in this report are the same as the global eXpeRience ones, applied to a Portuguese sub-population. Patients with uncontrolled allergic asthma who had started omalizumab within the previous 15 weeks were enrolled and received omalizumab add-on therapy for 24 months. The physicians’ global evaluation of treatment effectiveness (GETE), asthma symptoms and control (ACT score), quality of life (mini-AQLQ score), exacerbations, and serious adverse events (SAE) were reported.


Of the 943 patients recruited in the eXpeRience registry, 62 patients were from Portugal. 62.1% of them were observed to be responders with good/excellent GETE assessment at Week 16. Clinically meaningful improvements in asthma control (ACT score) and quality of life (mini-AQLQ score) were observed with omalizumab therapy at Months 12 (mean change: +7.7 [n = 35]; +2.1 [n = 20], respectively) and 24 (mean change: +7.0 [n = 26]; +2.7 [n = 13], respectively). Asthma symptoms and rescue medication usage were reduced to ≤1 day/week at Month 24 from a baseline of ≥3.5 days/week. The proportion of patients with no clinically significant exacerbations increased from 6.5% during pre-treatment (n = 62) to 50% at Month 12 (n = 54) and 60% at Month 24 (n = 45).


The findings from the Portugal subpopulation of eXpeRience registry confirm that omalizumab add-on therapy is efficacious and well tolerated in the management of uncontrolled persistent allergic asthma. Another pertinent issue is the fact that the Portuguese subpopulation response is similar to the international population average of the study.

Omalizumab, Allergic asthma, Anti-immunoglobulin E, Asthma control, Exacerbations, Observational study
Journal: Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma

This article belongs to the Journal: Pulmonology


  • Impact Factor: 1.731(2017)
  • 5-years Impact Factor: 1,334
  • SCImago Journal Rank (SJR):0,342
  • Source Normalized Impact per Paper (SNIP):549

Open Access

Creative Commons License
Pulmonology is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

+ info